Equity Overview
Price & Market Data
Price: $4.47
Daily Change: -$0.158 / 3.53%
Range: $4.13 - $4.47
Market Cap: $18,986,390
Volume: 62,302
Performance Metrics
1 Week: 0.36%
1 Month: 8.95%
3 Months: 17.36%
6 Months: -1.61%
1 Year: -49.57%
YTD: -13.59%
Company Details
Employees: 13
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.